Novartis Ag (NVS) FCF Margin (2009 - 2026)
Novartis Ag (NVS) posted FCF Margin of 38.6% for Q2 2026, down 63.63% sequentially from 106.13% in Q1 2026, and down 647.0% YoY from 7.06% in Q2 2025.
Novartis Ag (NVS) FCF Margin (2009 - 2026) Analysis & Trends
Novartis Ag has reported FCF Margin for 18 years, with the latest figure at 38.6% in Q2 2026.
- Quarterly FCF Margin fell 647.0% year-over-year to 38.6% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 44.27% (up 1565.0% YoY) and the FY2025 annual result came in at 32.27%, down 3.0% from the prior year.
- FCF Margin declined to 38.6% in Q2 2026 per NVS's latest filing, from 106.13% in the prior quarter.
- Over five years, FCF Margin peaked at 235.14% in Q3 2023 and troughed at 178.74% in Q1 2024.
- A 5-year average of 63.69% and a median of 45.06% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin soared 119052 bps in 2022, then sank 23059 bps in 2024.
- Over 5 years, FCF Margin stood at 1.21% in 2022, then soared by 51 bps to 1.83% in 2023, then soared by 1632 bps to 31.63% in 2024, then soared by 405 bps to 159.84% in 2025, then sank by 76 bps to 38.6% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 38.6%, 106.13%, and 159.84% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | 38.60% |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | -12.07% |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 34.70% |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | 44.00% |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 2.01% |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 3.90% |
| 10 | Sanofi | 54.98 Bn | 47.60 Bn | 10.79 Bn | 18.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.60% |
| Mar 31, 2026 | 106.13% |
| Dec 31, 2025 | 159.84% |
| Sep 30, 2025 | 87.62% |
| Jun 30, 2025 | 45.06% |
| Mar 31, 2025 | 203.20% |
| Dec 31, 2024 | 31.63% |
| Jun 30, 2024 | 41.04% |
| Mar 31, 2024 | -178.74% |
| Dec 31, 2023 | 1.83% |
| Sep 30, 2023 | 235.14% |
| Jun 30, 2023 | 33.23% |
| Mar 31, 2023 | 51.85% |
| Dec 31, 2022 | 1.21% |
| Sep 30, 2022 | 93.64% |
| Jun 30, 2022 | 31.39% |
| Mar 31, 2022 | 100.00% |
| Dec 31, 2021 | 1.81% |
| Sep 30, 2021 | -1,096.88% |
| Jun 30, 2021 | 34.59% |